BlueSphere Bio was founded upon the unique TCR discovery platform – TCXpress™, designed to isolate and functionally characterize TCRs with speed and efficiency. This platform will be used to identify panels of specific TCRs reactive against shared antigens in various clinical settings for use in either TCR-based cell therapy or in antibody-like molecules, such as bi-specific T cell engagers. BlueSphere anticipates filing its first IND application in 2023 for a novel TCR T-cell therapy for patients with high-risk leukemias in the context of allogeneic stem cell transplantation. Concurrent with its use for shared antigens, BlueSphere is deploying TCXpress™ and NEOXpress™, a proprietary patient-specific neoantigen discovery platform, to target patient-specific neoantigens and anticipates additional virtual patient data from multiple solid tumor types over the next several months.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
BSB-1001
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
